ChromaDex (NASDAQ:CDXC) Sets New 1-Year High on Analyst Upgrade

ChromaDex Co. (NASDAQ:CDXC) shares reached a new 52-week high on Wednesday after LADENBURG THALM/SH SH raised their price target on the stock from $6.80 to $8.10. LADENBURG THALM/SH SH currently has a buy rating on the stock. ChromaDex traded as high as $8.16 and last traded at $8.38, with a volume of 3436130 shares traded. The stock had previously closed at $5.60.

CDXC has been the topic of several other reports. StockNews.com upgraded shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a report on Monday, February 24th. Roth Mkm increased their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th.

Insider Activity at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of ChromaDex by 4.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 57,304 shares of the company’s stock worth $304,000 after buying an additional 2,196 shares during the last quarter. OneDigital Investment Advisors LLC raised its stake in ChromaDex by 5.5% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock worth $217,000 after purchasing an additional 3,097 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in ChromaDex by 3.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 144,621 shares of the company’s stock worth $767,000 after purchasing an additional 4,452 shares in the last quarter. USA Financial Formulas acquired a new stake in ChromaDex in the 4th quarter worth about $25,000. Finally, BSW Wealth Partners raised its stake in ChromaDex by 5.6% in the 4th quarter. BSW Wealth Partners now owns 93,847 shares of the company’s stock worth $498,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 15.41% of the company’s stock.

ChromaDex Trading Down 10.1 %

The firm’s 50 day simple moving average is $5.72 and its two-hundred day simple moving average is $5.15. The firm has a market cap of $587.39 million, a price-to-earnings ratio of 769.77 and a beta of 2.21.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.